Clinical Investigation Specialists, Inc. | Gurnee, IL

Research site

Site insights

Top conditions

Top treatments


Parent organization

This site is a part of Clinical Investigation Specialists, Inc.

Data sourced from

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 11 total trials

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

This is an interventional, randomized, double blind, parallel group, placebo-controlled, Phase 2b, 3-arm study to assess the effect of pegylated-reco...

Alopecia Areata
Drug: Rezpegaldesleukin
Drug: Placebo

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Acute Coronary Syndrome
Drug: Milvexian
Other: Placebo

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Atrial Fibrillation
Drug: Apixaban Placebo
Drug: Milvexian

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in particip...

Active, not recruiting
Cardiovascular Diseases
Drug: Placebo
Drug: Olezarsen

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Obicetrapib
Drug: Placebo

The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatmen...

Active, not recruiting
Drug: Placebo comparator dosing
Drug: Rimegepant 75mg every other day dosing

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Overweight and Obesity
Drug: Retatrutide
Drug: Placebo

Trial sponsors

Lilly logo
Janssen (J&J Innovative Medicine) logo
Pfizer logo
Ionis Pharmaceuticals logo
Nektar Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems